Alzheimer’s Disease 2024: The Role of Biomarkers

The field of Alzheimer’s disease is evolving rapidly, and laboratory testing is now playing a major role in diagnosis and treatment decisions. Early, accurate diagnosis is important to access FDA-approved medications and improve patient care, but the plethora of lab test options can be confusing. Blood and cerebrospinal fluid (CSF) options exist that have shown high concordance with amyloid positron emission tomography (PET) scans, but careful consideration should be put into ordering the right test for the right patient.
This webinar, with expert presenters who have both extensive lab and clinical experience, will discuss the latest updates in Alzheimer’s disease diagnostic criteria as well as a comprehensive review of the laboratory testing landscape to help listeners better understand their options.